1Kolb Hj, Mittermueller J, Clem C, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood, 1990;76:2462
2Porter DL, Antin JH. The graft-versus-leukemia effects of allogeneic cell therapy. Annu Rev Med,1999;50:369
3Tanaka J, Imamura M, Kasai M,et al. The important balance between cytokines derived from type 1 and type 2 helper T cells in the control of graft-versus-host disease. Bone Marrow Transplant, 1997;19(6):571
4Munker R, Lubbert M, Yonehara S,et al. Expression of the Fas antigen on primary human leukemia cells. Ann Hematol, 1995;70(1):15
5Susskind B, Shornick MD, Iannotti MR, et al. Cytolytic effector mechanisms of human CD4+cytotoxic T lymphocytes. Hum Immunol,1996;45(1):64
6Slavin S, Naparstek E, Nagler A, et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood, 1996 15;87(6):2195
7Schleuning M. Adoptive allogeneic immunotherapy--history and future perspectives. Transfus Sci,2000;23(2):133
8Waller EK, Redei I, Yeager AM, et al. 7.5Gy irradiation attenuates the graft-versus-host disease potential of allogeneic lymphocytes while preserving antileukemic activity in preclinical and clinical studies. The 39th Annual Meeting of Hematology, San Die
9Guerriero A, Boyer M, Waller EK. γ-Irradiation activates NF-κB in human T cells. The 39th Annual Meeting of Hematology, San Diego, 1997:37
10Igietseme JU, Smith K, Simmons A, et al. Effect of gamma-irradiation on the effector function of T lymphocytes in microbial control. Int J Radiat Biol, 1995;67(5):557
1Ruggeri L,Capanni M,Urbani E,et al.Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants[J].Science,2002,295(5562):2097-2100.
2Lokhorst H M,Schattenberg A,Cornelissen J J,et al.Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transportation[J].Blood,1997,90(10):4206-4211.
3Khouri I F,Romaguera J,Kantarjian H,et al.Hyper-CVAD and high-dose methotrexato/cytaranbine followed by stem-cell transplatation:an active regimen for aggressive mantal-cell lymphoma[J].J Clin Oncol,1998,16:3803-3809.
4Ezzat A A,Khalifa F,Berry J,et al.ESHAP:an effective treatment in selected patients with relapsed non -Hodgkin' lymphoma[J].Ann Oncol,1994,5:45-46.
6Miller T P,Dahlberg S,Cassady J R,et al.Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate-and high-grade non-Hodgkin's lymphoma[J].N Engl J Med,1998,339(1):21-26.
7Morecki S,Ellaena Y,Adi D,et al.Allogeneic cell therapy for a murine mammary carcinoma[J].Cancer Res,1998,58:3891-3895.
8Leung W,Iyengar R,Turner V,et al.Determinants of antileukemia effects of allogeneic NK cells[J].Immumol,2004,172(1):644-650.
9Leis J,Porter D L.Unrelated donor leukocyte infusions to treat relapse after unrelated donor bone marrow transplantation[J].Leuk Lymphoma,2002,4(3):9-17.
10Hadar E,Bitan M,Resnick I B,et al.Safety and efficacy of donor lymphocyte infusions following mismatched stem cell transportation[J].Biol Blood Marrow Transplant,2006,12:1295-1301.
